Virus therapy takes on deadly brain cancer

NCT ID NCT06763965

ENROLLING_BY_INVITATION Disease control Sponsor: Beijing Bio-Targeting Therapeutics Technology Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a modified virus (BioTTT001) injected directly into brain tumors in 30 adults with recurrent high-grade glioma. The goal is to see if it is safe, how it spreads in the body, and whether it can help control the cancer. Participants will receive multiple injections, and researchers will monitor side effects and survival rates.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BioTTT001 (a modified virus that targets and kills cancer cells and boosts immune response)
What this could lead to: If successful, this could offer a new treatment option for patients with recurrent high-grade glioma, potentially extending survival.
What could go wrong: This is an early-phase trial with only 30 participants, so results may not apply broadly. The virus may cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT HIGH GRADE GLIOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adenoviridae infectious disease glioma malignant glioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECURRENT HIGH GRADE GLIOMA

Contacts and locations

Show contact details

Locations

Sanbo Brain Hospital, Capital Medical University

Beijing, Chaoyang District, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.